APVO Stock Plunges 30.9% on Reverse Split Amid Delisting Fears

The share price fell to its lowest level since May 2025 today, with an intraday decline of 10.78%.

Aptevo Therapeutics (APVO) announced a 1-for-18 reverse stock split, reducing shares from 18 million to 1 million, effective December 29. The move aims to meet Nasdaq listing requirements and stabilize the stock, which has fallen 44.29% to $0.5181. A 30.9% premarket drop underscores investor concerns over financial stability and long-term viability.

APVO’s stock has plummeted 99% year-to-date, with a $15.67 million market cap and negative earnings. The reverse split addresses delisting risks but does not resolve challenges like limited revenue and high development costs. Equity adjustments post-split could dilute shareholder value and complicate fundraising.

Positive clinical data includes a 93% response rate in the RAINIER trial for Mipletamig in AML and preclinical success with APVO451. Collaborations with Alligator Bioscience on ALG.APV-527 also highlight innovation. However, commercial viability remains unproven, and regulatory hurdles persist.

Market sentiment is divided; while the split may attract investors, it also signals distress. Reduced liquidity and reliance on clinical milestones heighten volatility. APVO remains a high-risk, high-reward investment, with future outcomes hinging on trial progress and regulatory approvals.